{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["hepatocellular carcinoma"],"disease":["Hepatocellular Carcinoma"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/38658"],"location":["China"],"study_start_month":["5"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Effects of intestinal microflora transplantation on the efficacy of PD-1 monoclonal antibody combined with TKI in the treatment of patients with secondary drug resistance to advanced liver cancer","description":"Interventions: Experimental group:Tirelizumab combined with TKI therapy, after disease control, patients with further progression were treated with intestinal flora transplantation based on the original regimen\nPrimary outcome(s): Disease control rate\nStudy Design: Single arm","dates":{"creation":"2022-05-15"},"accession":"38658","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2200058471"]}}